QLT announces encouraging Phase II data from core study of Punctal Plug Drug Deliv...(forts are focused on pharmaceutical prod...),Health

Date:10/28/2008

forts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our website at http://www.qltinc.com.

QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.

Atrigel is a registered trademark of QLT USA, Inc.

Visudyne is a registered trademark of Novartis AG.

Eligard is a registered trademark of Sanofi-aventis.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

Certain statements in this press release constitute "forward looking statements" of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward looking information" within the meaning of applicable Canadian securities laws. Forward looking statements include, but are not limited to: our expectations for timing to receive data from our CORE study; further investigations that we intend to conduct in our CORE study; our future expectations about our punctal plug delivery system; and statements which contain language such as: "assuming," "prospects," "future," "projects," "believes," "expects" and "outlook." Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company's future operating results are uncertain and likely to fluctuate; uncertainties relating to the timing and results of th
'/>"/>

SOURCE QLT Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Response Biomedical Announces Insider Participation in Current Financing
2. American National Announces Third Quarter 2008 Results
3. Digestive Care, Inc. Announces the Complete Submission of the NDA for PANCRECARB(R) (pancrelipase)
4. U.S. Preventive Medicine(R) Announces Major Development for The Prevention Plan(TM)
5. Haemonetics Announces Promotion of Brian Concannon to CEO Effective April 2009
6. HLTH Corporation Announces Commencement of Its Tender Offer
7. ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia
8. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
9. UCSF Chancellor J. Michael Bishop Announces Plan To Step Down
10. USC Cancer Center Announces Contribution By Larry and Judy Freeman
11. Sikorsky Aircraft Announces Contract with Boston MedFlight for S-76C++(TM) Helicopter